MX378947B - Composición farmacéutica estable para administración oral. - Google Patents

Composición farmacéutica estable para administración oral.

Info

Publication number
MX378947B
MX378947B MX2017016862A MX2017016862A MX378947B MX 378947 B MX378947 B MX 378947B MX 2017016862 A MX2017016862 A MX 2017016862A MX 2017016862 A MX2017016862 A MX 2017016862A MX 378947 B MX378947 B MX 378947B
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
oral administration
stable pharmaceutical
compound
acceptable salt
Prior art date
Application number
MX2017016862A
Other languages
English (en)
Other versions
MX2017016862A (es
Inventor
Fumiaki UEJO
Mazakazu MIYAZAKI
Ryohei Ishiba
Yuki Takaishi
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57686183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX378947(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2017016862A publication Critical patent/MX2017016862A/es
Publication of MX378947B publication Critical patent/MX378947B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporciona una composición farmacéutica estable para administración oral que comprende 6-etil-3-({3-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]fenil}amino)-5-(tetrahidro-2H-piran-4-ilamino)pirazin-2-carboxamida (de aquí en adelante referida como compuesto A) o una sal farmacéuticamente aceptable de la misma, en donde se inhibe la generación de sustancias relacionadas durante el almacenamiento. En la composición farmacéutica estable para administración oral, la proporción de cristales de compuesto A o una sal farmacéuticamente aceptable de la misma es 60% o más con respecto a la cantidad total del Compuesto A o una sal farmacéuticamente aceptable del mismo.
MX2017016862A 2015-07-03 2016-07-01 Composición farmacéutica estable para administración oral. MX378947B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015134817 2015-07-03
PCT/JP2016/069615 WO2017006855A1 (ja) 2015-07-03 2016-07-01 安定な経口投与用医薬組成物

Publications (2)

Publication Number Publication Date
MX2017016862A MX2017016862A (es) 2018-04-24
MX378947B true MX378947B (es) 2025-03-11

Family

ID=57686183

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016862A MX378947B (es) 2015-07-03 2016-07-01 Composición farmacéutica estable para administración oral.

Country Status (21)

Country Link
US (9) US10786500B2 (es)
EP (2) EP4230208A1 (es)
JP (2) JP6132294B1 (es)
KR (1) KR102685890B1 (es)
CN (1) CN107847500B (es)
CA (1) CA2989534C (es)
DK (1) DK3318259T3 (es)
ES (1) ES2940306T3 (es)
FI (1) FI3318259T3 (es)
HR (1) HRP20230253T1 (es)
HU (1) HUE061697T2 (es)
LT (1) LT3318259T (es)
MX (1) MX378947B (es)
PH (1) PH12017502252B1 (es)
PL (1) PL3318259T3 (es)
PT (1) PT3318259T (es)
RS (1) RS64070B1 (es)
SI (1) SI3318259T1 (es)
SM (1) SMT202300074T1 (es)
TW (1) TWI756177B (es)
WO (1) WO2017006855A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3103453T (lt) * 2014-02-04 2020-05-11 Astellas Pharma Inc. Vaisto kompozicija, apimanti diamino heterociklinį karboksamido junginį kaip aktyvų ingredientą
SI3318259T1 (sl) * 2015-07-03 2023-06-30 Astellas Pharma Inc. Stabilni farmacevtski sestavki za oralno dajanje
PL3949952T3 (pl) 2019-04-03 2024-10-14 Astellas Pharma Inc. Kompozycja farmaceutyczna
WO2022009235A1 (en) * 2020-07-10 2022-01-13 Msn Laboratories Private Limited, R&D Center Process for the preparation of gilteritinib fumarate
JP2025502748A (ja) 2021-12-30 2025-01-28 バイオメア フュージョン，インコーポレイテッド Ｆｌｔ３の阻害剤としてのピラジン化合物
WO2025240494A1 (en) 2024-05-13 2025-11-20 Lumen Bioscience, Inc. Leptin compositions and methods of making and using the same to support weight loss and/or maintenance

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009084678A1 (ja) * 2007-12-28 2009-07-09 Sawai Pharmaceutical Co., Ltd. 口腔内崩壊錠およびその製造方法
CA2760061C (en) * 2009-05-08 2017-02-28 Astellas Pharma Inc. Diamino heterocyclic carboxamide compound
PH12013501442B1 (en) * 2011-01-07 2018-04-20 Novartis Ag Immunosuppressant formulations
LT3103453T (lt) 2014-02-04 2020-05-11 Astellas Pharma Inc. Vaisto kompozicija, apimanti diamino heterociklinį karboksamido junginį kaip aktyvų ingredientą
TW201613579A (en) 2014-06-24 2016-04-16 Astellas Pharma Inc Pharmaceutical composition for oral administration
SI3318259T1 (sl) 2015-07-03 2023-06-30 Astellas Pharma Inc. Stabilni farmacevtski sestavki za oralno dajanje
US9755832B2 (en) 2015-12-29 2017-09-05 International Business Machines Corporation Password-authenticated public key encryption and decryption

Also Published As

Publication number Publication date
FI3318259T3 (fi) 2023-03-20
US11938132B2 (en) 2024-03-26
ES2940306T3 (es) 2023-05-05
US20200383977A1 (en) 2020-12-10
PH12017502252B1 (en) 2023-10-11
CA2989534A1 (en) 2017-01-12
RS64070B1 (sr) 2023-04-28
CA2989534C (en) 2023-08-01
PT3318259T (pt) 2023-03-20
EP3318259A4 (en) 2019-02-27
SI3318259T1 (sl) 2023-06-30
PL3318259T3 (pl) 2023-05-02
US11938131B2 (en) 2024-03-26
SMT202300074T1 (it) 2023-05-12
US11944620B2 (en) 2024-04-02
US11938133B2 (en) 2024-03-26
CN107847500A (zh) 2018-03-27
TW201716069A (zh) 2017-05-16
US20230277529A1 (en) 2023-09-07
TWI756177B (zh) 2022-03-01
DK3318259T3 (en) 2023-03-06
US20180185359A1 (en) 2018-07-05
RU2018103354A3 (es) 2019-11-28
EP4230208A1 (en) 2023-08-23
PH12017502252A1 (en) 2018-05-28
CN107847500B (zh) 2021-08-10
WO2017006855A1 (ja) 2017-01-12
JP6132294B1 (ja) 2017-05-24
US20230301992A1 (en) 2023-09-28
HRP20230253T1 (hr) 2023-04-28
US20230129146A1 (en) 2023-04-27
EP3318259B1 (en) 2023-01-11
RU2018103354A (ru) 2019-08-05
HUE061697T2 (hu) 2023-08-28
JPWO2017006855A1 (ja) 2017-07-13
KR20180023914A (ko) 2018-03-07
JP6798400B2 (ja) 2020-12-09
US20230277531A1 (en) 2023-09-07
US11938130B2 (en) 2024-03-26
HK1248544A1 (zh) 2018-10-19
LT3318259T (lt) 2023-05-10
JP2017119728A (ja) 2017-07-06
US20230277532A1 (en) 2023-09-07
RU2764750C2 (ru) 2022-01-20
KR102685890B1 (ko) 2024-07-19
MX2017016862A (es) 2018-04-24
US20230310422A1 (en) 2023-10-05
US20230277530A1 (en) 2023-09-07
US10786500B2 (en) 2020-09-29
EP3318259A1 (en) 2018-05-09

Similar Documents

Publication Publication Date Title
MX378947B (es) Composición farmacéutica estable para administración oral.
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
EA201490014A1 (ru) Модифицированное высвобождение 4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]амино]-n-[5-(4-метил-1h-имидазол-1-ил)-3-(трифторметил)фенил]бензамида, солюбилизированного с использованием органических кислот
PH12019500395A1 (en) Amino-pyrrolopyrimidinone compounds and methods of use thereof
UA112317C2 (uk) Похідні 2-(1,2,3-триазол-2-іл)бензаміду та 3-(1,2,3-триазол-2-іл)піколінаміду як антагоністи рецептора орексину
EA202091262A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
MX2014014710A (es) Compuestos de n-alquiltriazol como antagonistas del receptor del acido lisofosfatidico (lpar).
GEP20156351B (en) Glucagon receptor modulator
UA110310C2 (uk) Сполуки n-арилтриазолу як антагоністи рецепторів лізофосфатидної кислоти (lpar)
MX2017002967A (es) Composicion farmaceutica novedosa que contiene derivado de acido hidroxamico o sal del mismo.
EA201891267A1 (ru) Фармацевтическая композиция, содержащая действенный ингибитор urat1
PE20100050A1 (es) Forma de dosificacion farmaceutica para la liberacion inmediata de un derivado de indolinona
PE20160550A1 (es) Formulaciones de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona
EA201690888A1 (ru) Новые гетероциклические соединения
CY1119687T1 (el) Κρυσταλλικο αλας της (s)-(2-(6-χλωρο-7- μεθυλ-1η- βενζο [d]imiδazoλ-2- υλ)-2- μεθυλπυρρολιδιν-1- υλ)(5-μεθοξυ-2-(2η-1,2,3- τριαζολ-2- υλ)φαινυλ) μεθανονης ως ανταγωνιστης υποδοχεα ορεξινης
PH12014502364A1 (en) Substituted pyrazole compounds as lpar antagonists
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
MY174648A (en) Formulations of organic compounds
EA201692298A1 (ru) Производные карбоксамидов
EA201300857A1 (ru) Пиразолы в качестве антагонистов crth2
PH12017501832A1 (en) Stabilized pharmaceutical composition
NZ705340A (en) Amine salt and crystals thereof
MY183976A (en) Pharmaceutical composition for oral administration with improved dissolution and/or absorption
TH148311A (th) การปลดปล่อยที่ถูกดัดแปรของ 4-เมธิล-3-[[4-(3-ไพริดินิล)-2-ไพริมิดินิล]อะมิโน]-n-[5-(4-เมธิล-1h-อิมิดาโซล-1-อิล)-3-(ไตรฟูลออโรเมธิล)ฟีนิล] เบนซาไมด์ที่สามารถละลายได้โดยใช้กรดอินทรีย์